Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America
  • Clinical and pharmacological profile of benznidazole for treatment of Chagas disease
  • Safety, efficacy, and pharmacokinetics of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase-II clinical trial

RSS PRESS RELEASES

  • New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier
  • DNDi and Fiocruz launch project to expand access to diagnosis and treatment for Chagas disease in Brazil
  • FIND and DNDi team up to support Malaysian MOH efforts to simplify and decentralize hepatitis C screening & treatment

RSS NEWS

  • 11th DNDi Partners’ Meeting celebrates African leadership in innovation for R&D and access to medicines
  • Joelle Tanguy appointed Director of External Relations at DNDi
  • Inaugural DNDi training for health & science journalists in Kampala

RSS IN THE MEDIA

  • IP Watch: “‘The People’s Prescription’: New Report Calls For Value Creation Instead Of Value Extraction In Pharmaceutical R&D”
  • UCL News: “The health innovation system is ‘broken’ and failing patients”
  • Der Tagesspiegel: “Gipfel für globale Gesundheit”

RSS EVENTS

  • International Conference on Innovations for the Elimination and Control of Visceral Leishmaniasis (IEC-VL)
  • 5th Symposium on Drug Design and Development for Neglected Diseases
  • ASTMH 2018

RSS Scientific Articles

  • The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America
  • Clinical and pharmacological profile of benznidazole for treatment of Chagas disease
  • Safety, efficacy, and pharmacokinetics of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase-II clinical trial
  • Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

Social Mission Ration 2017

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close